Sugi Predict

Sugi Predict / Compounds / SCHEMBL4643669

SCHEMBL4643669

SCHEMBL4643669

Cc1nc(-c2ccccc2)cc(=O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 3/20 0.72
▸ XDH P47989 5/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.63
▸ ALDH1A1 P00352 2/20 0.58
▸ MAPK1 P28482 2/20 0.55
▸ GAA P10253 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ ADORA3 P0DMS8 1/20 0.54
▸ ADORA2A P29274 1/20 0.54
▸ ADORA1 P30542 1/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ HSD17B10 Q99714 3/20 0.53
▸ KDM4E B2RXH2 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ MEN1 O00255 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4748429 0.85 GSK3B (0.72) GSK3BXDHSMN1; SMN2ALDH1A1GAA
SCHEMBL5377975 0.84 GSK3B (1.00) GSK3BXDHSMN1; SMN2MAPK1
SCHEMBL5400045 0.83 GSK3B (0.69) GSK3BXDHSMN1; SMN2ALDH1A1KMT2A
SCHEMBL4822785 0.79 GSK3B (0.84) GSK3BXDHSMN1; SMN2ALDH1A1MAPK1
SCHEMBL28132422 0.78 GSK3B (0.70) GSK3BXDHSMN1; SMN2ALDH1A1MAPK1
SCHEMBL2403432 0.78 XDH (1.00) GSK3BXDHSMN1; SMN2
SCHEMBL5659777 0.77 SMN1; SMN2 (1.00) GSK3BXDHSMN1; SMN2ALDH1A1GAA
SCHEMBL26039905 0.77 ALDH1A1 (0.70) GSK3BXDHSMN1; SMN2ALDH1A1GAA
SCHEMBL14063546 0.77 GSK3B (0.74) GSK3BXDHSMN1; SMN2ALDH1A1MAPK1
SCHEMBL29310490 0.76 GSK3B (0.79) GSK3BXDHSMN1; SMN2ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466805-B2 Pharmaceutical compounds ALMAC DISCOVERY LIMITED (GB) 2025-11-11 — — US disclosed
WO-2024173343-A1 COMPOUNDS TARGETING HYDROXYSTEROID 17-BETA DEHYDROGENASE (HSD17B) AND USES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2024-08-22 — — WO disclosed
CN-109790146-B Pharmaceutical compounds 阿尔麦克探索有限公司 2022-08-23 — — CN disclosed
EP-3490982-B1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LTD (GB) 2022-04-20 — — EP disclosed
US-20220002264-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2022-01-06 — — US disclosed
CN-113395965-A USP19 inhibitors for treatment 阿尔麦克探索有限公司 2021-09-14 — — CN disclosed
US-11053213-B2 Pharmaceutical compounds ALMAC DISCOVERY LIMITED (GB) 2021-07-06 — — US disclosed
US-20190233394-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2019-08-01 — — US disclosed
US-8288398-B2 Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones MERCK SERONO SA (CH) 2012-10-16 — — US disclosed
US-8288398-B2 Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones MERCK SERONO SA (CH) 2012-10-16 — — US disclosed
US-20080287474-A1 Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones LABORATOIRES SERONO SA (CH) 2008-11-20 — — US disclosed
US-20080287474-A1 Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones LABORATOIRES SERONO SA (CH) 2008-11-20 — — US disclosed
US-7429604-B2 Six-membered heterocycles useful as serine protease inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2008-09-30 — — US disclosed
US-20080221103-A1 New heterocyclic compounds ORCHID RESEARCH LABORATORIES LTD. (IN) 2008-09-11 — — US disclosed
EP-1957469-A1 ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES Laboratoires Serono SA (CH) 2008-08-20 — — EP disclosed
WO-2007065940-A1 ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES LABORATOIRES SERONO S.A. (CH) 2007-06-14 — — WO disclosed
WO-2007065940-A1 ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES LABORATOIRES SERONO S.A. (CH) 2007-06-14 — — WO disclosed
EP-0153746-B1 3-AMINO-2-HYDROXYPROPYL DERIVATIVES OF PYRIMIDIN-4-ONE MERCK & CO. INC. (US) 1990-11-22 — — EP disclosed
US-4598149-A ADRENERGIC BLOCKING AGENTS MERCK & CO., INC. (US) 1986-07-01 — — US disclosed
EP-0153746-A2 3-Amino-2-hydroxypropyl derivatives of pyrimidin-4-one MERCK & CO. INC. (US) 1985-09-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466805-B2 Pharmaceutical compounds USP19, USP18, UBE2I GSK3B 1877/4885XDH 796/4885SMN1; SMN2 2586/4885
US-20080287474-A1 Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones TYMP, DHFR, DPYD GSK3B 4761/4885XDH 409/4885SMN1; SMN2 1687/4885
US-20190233394-A1 PHARMACEUTICAL COMPOUNDS USP19, USP18, UBE2I GSK3B 1877/4885XDH 796/4885SMN1; SMN2 2586/4885
US-20220002264-A1 PHARMACEUTICAL COMPOUNDS USP19, USP18, UBE2I GSK3B 1877/4885XDH 796/4885SMN1; SMN2 2586/4885
US-11053213-B2 Pharmaceutical compounds USP19, USP18, UBE2I GSK3B 1877/4885XDH 796/4885SMN1; SMN2 2586/4885
US-20080221103-A1 New heterocyclic compounds LOXL4, CXCR4, LTC4S GSK3B 85/4885XDH 55/4885SMN1; SMN2 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.